Obesity pipeline
Trial arms side by side.
One row is one arm. A blank cell is n/r. A comparator gap appears only when the source states that gap.
ClassNone selected
MechanismNone selected
No arms selected. Choose a drug, an arm, or a preset.
Each arm uses its closest stored timepoint inside the window.
value
Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.
No selected arm has this endpoint inside the time window.
Show as table
| Arm | Trial | Phase | Population | n | Comparator | Timepoint | Estimand | Assessor | Value |
|---|
Not shown
Every selected arm is drawn.
299 of 2118 arms with a reported figure. Choose arms to narrow the chart.
Participants, %
Source: Cited trial source. A count is not drawn as a percent unless the arm size is stored.
X axis: arm. Y axis: participants, %.
Show as table
| Arm | Any adverse event, % | Serious adverse event, % | Discontinued for an adverse event, % | Nausea, % | Vomiting, % | Diarrhea, % |
|---|---|---|---|---|---|---|
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 7.2 mg | n/r | n/r | 5.4% | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Placebo | n/r | n/r | 1% | n/r | n/r | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Placebo (semaglutide) | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 1.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide placebo I/II | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Placebo, in trial | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 15 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide placebo OW | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Placebo, in trial | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Insuline glargine U100 (reduced) + semaglutide | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Insuline glargine U100 (titrated) | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Placebo (semaglutide) | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 7.2 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 1.7 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 1.7 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Placebo (semaglutide) | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Placebo, in trial | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Placebo (semaglutide) | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide, on treatment | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Placebo, on treatment | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide 5 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide 10 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide 15 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide 15 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide 10 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Tirzepatide (lead-in) | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Tirzepatide MTD | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Tirzepatide | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Tirzepatide | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Tirzepatide MTD_GPI1 | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Placebo_GPI1 | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Tirzepatide MTD_GPI2 | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Placebo_GPI2 | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide 15 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide 10 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide 15 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide 10 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Orforglipron Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Orforglipron 6 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Orforglipron 12 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Orforglipron Placebo QD | n/r | n/r | n/r | n/r | n/r | n/r |
| Orforglipron 6 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Orforglipron 12 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Cagrilintide/semaglutide cagrilintide 2.4 mg and semaglutide 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Cagrilintide/semaglutide Placebo s.c. | n/r | n/r | n/r | n/r | n/r | n/r |
| Retatrutide 4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Retatrutide 9 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Retatrutide 12 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Retatrutide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Survodutide 3.6 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Survodutide 6.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Survodutide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Survodutide 0.6 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Survodutide Placebo group | n/r | n/r | n/r | n/r | n/r | n/r |
| Survodutide 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Survodutide 3.6 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Survodutide 4.8 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| VK2735 2.5 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| VK2735 15 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| VK2735 Placebo 13 weeks | n/r | n/r | n/r | n/r | n/r | n/r |
| Eloralintide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Eloralintide 1 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Eloralintide 3 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Eloralintide 6 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Eloralintide 9 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Berobenatide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Dulaglutide Dulaglutide Arm | n/r | n/r | n/r | n/r | n/r | n/r |
| Dulaglutide Placebo Arm | n/r | n/r | n/r | n/r | n/r | n/r |
| Exenatide Group A | n/r | n/r | n/r | n/r | n/r | n/r |
| Exenatide Group B | n/r | n/r | n/r | n/r | n/r | n/r |
| Exenatide Exenatide | n/r | n/r | n/r | n/r | n/r | n/r |
| Exenatide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Exenatide Exenatide once weekly (EQW ) | n/r | n/r | n/r | n/r | n/r | n/r |
| Exenatide Dapagliflozin (DAPA) | n/r | n/r | n/r | n/r | n/r | n/r |
| Exenatide EQW plus DAPA | n/r | n/r | n/r | n/r | n/r | n/r |
| Exenatide Dapagliflozin plus Glucophage (MET ER) | n/r | n/r | n/r | n/r | n/r | n/r |
| Exenatide Phentermine /Topiramate (PHEN/ TPM) ER | n/r | n/r | n/r | n/r | n/r | n/r |
| Exenatide Exenatide once weekly extended-release | n/r | n/r | n/r | n/r | n/r | n/r |
| Exenatide Matching placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Exenatide Group A | n/r | n/r | n/r | n/r | n/r | n/r |
| Exenatide Group B | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 3.0mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 3.0mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Liraglutide Placebo, no Pre-diabetes | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Liraglutide Placebo, Pre-diabetes | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 1.8 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Semaglutide | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Liraglutide | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Placebo (liraglutide) | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Liraglutide | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Placebo, in trial | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Liraglutide | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Metformin XR plus liraglutide | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Metformin XR plus placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Liraglutide Pen Injector (Saxenda) | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Placebo liraglutide pen injector | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Liraglutide | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 0.05 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 0.1 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 0.2 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 0.3 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 0.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Placebo + Metformin | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Liraglutide + Metformin | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 100 mcg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 200 mcg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 300 mcg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 4.5 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 1.2 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 0.6 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 0.3 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Orlistat | n/r | n/r | n/r | n/r | n/r | n/r |
| Lixisenatide Lixisenatide | n/r | n/r | n/r | n/r | n/r | n/r |
| Lixisenatide Sitagliptin | n/r | n/r | n/r | n/r | n/r | n/r |
| Mazdutide 3/6 Milligrams (mg) Mazdutide | n/r | n/r | n/r | n/r | n/r | n/r |
| Mazdutide 10 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Mazdutide 16 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Mazdutide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Mazdutide 6 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Oral Semaglutide Oral semaglutide | n/r | n/r | n/r | n/r | n/r | n/r |
| Oral Semaglutide Oral semaglutide placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Oral Semaglutide 25 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Oral Semaglutide Oral semaglutide placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Oral Semaglutide 50 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Oral Semaglutide oral semaglutide placebo once daily | n/r | n/r | n/r | n/r | n/r | n/r |
| TERN-601 250 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| TERN-601 500 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| TERN-601 750 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| TERN-601 Matching Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| CT-868 CT-868 Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| CT-868 1.8 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| CT-868 4.1 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| CT-868 6.6 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| HM15211 HM15211 | n/r | n/r | n/r | n/r | n/r | n/r |
| HM15211 Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Pramlintide Placebo-P + Placebo-M | n/r | n/r | n/r | n/r | n/r | n/r |
| Pramlintide 360 mcg | n/r | n/r | n/r | n/r | n/r | n/r |
| Pramlintide 5.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Pramlintide 2.5 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Pramlintide 5.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Pramlintide 1.25 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Pramlintide 2.5 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Pramlintide 5.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Pramlintide 1 | n/r | n/r | n/r | n/r | n/r | n/r |
| Pramlintide 2 | n/r | n/r | n/r | n/r | n/r | n/r |
| Pramlintide 3 | n/r | n/r | n/r | n/r | n/r | n/r |
| Pramlintide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Pramlintide Pramlintide + Metreleptin | n/r | n/r | n/r | n/r | n/r | n/r |
| Pramlintide Pramlintide Acetate and Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Pramlintide Lead-In Period | n/r | n/r | n/r | n/r | n/r | n/r |
| Bimagrumab 30 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Bimagrumab 30 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Bimagrumab 30 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Bimagrumab 1.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Bimagrumab 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Bimagrumab 1.0 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Bimagrumab 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion NB16 | n/r | n/r | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion NB32 | n/r | n/r | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion NB32 | n/r | n/r | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion NB32 | n/r | n/r | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion NB32 | n/r | n/r | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion BWL + NB medication | n/r | n/r | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion BWL + Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication | n/r | n/r | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion BWL + Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion NB medication | n/r | n/r | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion Naltrexone+Bupropion Medication | n/r | n/r | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion Naltrexone/Bupropion | n/r | n/r | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Orlistat Intensive Lifestyle Mod. Intervention | n/r | n/r | n/r | n/r | n/r | n/r |
| Orlistat Standard Lifestyle Intervention | n/r | n/r | n/r | n/r | n/r | n/r |
| Orlistat Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Orlistat Orlistat | n/r | n/r | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate VI-0521 Low | n/r | n/r | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate VI-0521 Top | n/r | n/r | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate VI-0521 Top | n/r | n/r | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate VI-0521 Mid | n/r | n/r | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate TPM 46 | n/r | n/r | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate TPM 92 | n/r | n/r | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate PHEN 7.5 | n/r | n/r | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate PHEN 15 | n/r | n/r | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate LSMT 12 | n/r | n/r | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate LSMT 24 | n/r | n/r | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate Phentermine & Topiramate | n/r | n/r | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate Placebo Drugs | n/r | n/r | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate Semaglutide | n/r | n/r | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate Other anti-obesity medication | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Setmelanotide | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Setmelanotide | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Setmelanotide (Double-Blind) | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Placebo (Double-Blind) | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Setmelanotide (Open-label) | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Pivotal Cohort | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 2 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 2.5 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 3 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 20 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 25 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 3 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 30 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 20 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 25 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 30 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Setmelanotide | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Setmelanotide | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Setmelanotide: PPL Group | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Setmelanotide: BBS Group | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 16p11.2 Cohort | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide AS Cohort | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide BBS Cohort | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide MC4R Cohort | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide POMC/PCSK1/LEPR Heterozygous Cohort | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide POMC/PCSK1/LEPR Composite Heterozygous Cohort | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide POMC/PCSK1/LEPR Compound Heterozygous Cohort | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide SH2B1 Cohort | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide SMS Cohort | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide SRC1 Cohort | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Stage 1: Setmelanotide (Open-Label) | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Stage 2: Setmelanotide (Double-Blind) | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Stage 2: Placebo (Double-Blind) | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Setmelanotide | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 0.5 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 1.5 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 2.5 mg | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Sibutramine Sibutramine | n/r | n/r | n/r | n/r | n/r | n/r |
| Sibutramine Placebo | n/r | n/r | n/r | n/r | n/r | n/r |
| Tesofensine placebo arm | n/r | n/r | n/r | n/r | n/r | n/r |
Not shown
- Semaglutide 2.4 mg: no arm n for percent
- Semaglutide Semaglutide placebo: no arm n for percent
- Semaglutide 2.4 mg: no arm n for percent
- Semaglutide Semaglutide: no arm n for percent
- Semaglutide Placebo (semaglutide): no arm n for percent
- Semaglutide 1.0 mg: no arm n for percent
- Semaglutide 2.4 mg: no arm n for percent
- Semaglutide Semaglutide placebo I/II: no arm n for percent
- Semaglutide Semaglutide: no arm n for percent
- Semaglutide Placebo: no arm n for percent
- Semaglutide 2.4 mg: no arm n for percent
- Semaglutide Placebo, in trial: no arm n for percent
- Semaglutide 15 mg: no arm n for percent
- Semaglutide 2.4 mg: no arm n for percent
- Semaglutide 2.4 mg: no arm n for percent
- Semaglutide Semaglutide placebo OW: no arm n for percent
- Semaglutide Semaglutide: no arm n for percent
- Semaglutide Semaglutide placebo: no arm n for percent
- Semaglutide 2.4 mg: no arm n for percent
- Semaglutide Placebo, in trial: no arm n for percent
- Semaglutide Insuline glargine U100 (reduced) + semaglutide: no arm n for percent
- Semaglutide Insuline glargine U100 (titrated): no arm n for percent
- Semaglutide Semaglutide: no arm n for percent
- Semaglutide Placebo (semaglutide): no arm n for percent
- Semaglutide 7.2 mg: no arm n for percent
- Semaglutide 2.4 mg: no arm n for percent
- Semaglutide Placebo: no arm n for percent
- Semaglutide 2.4 mg: no arm n for percent
- Semaglutide 2.4 mg: no arm n for percent
- Semaglutide 2.4 mg: no arm n for percent
- Semaglutide 2.4 mg: no arm n for percent
- Semaglutide 1.7 mg: no arm n for percent
- Semaglutide 1.7 mg: no arm n for percent
- Semaglutide Semaglutide: no arm n for percent
- Semaglutide Placebo (semaglutide): no arm n for percent
- Semaglutide Semaglutide: no arm n for percent
- Semaglutide Placebo: no arm n for percent
- Semaglutide 2.4 mg: no arm n for percent
- Semaglutide Placebo, in trial: no arm n for percent
- Semaglutide Placebo: no arm n for percent
- Semaglutide 2.4 mg: no arm n for percent
- Semaglutide Semaglutide: no arm n for percent
- Semaglutide Placebo (semaglutide): no arm n for percent
- Semaglutide Semaglutide: no arm n for percent
- Semaglutide Placebo: no arm n for percent
- Semaglutide 2.4 mg: no arm n for percent
- Semaglutide Placebo: no arm n for percent
- Semaglutide Semaglutide, on treatment: no arm n for percent
- Semaglutide Placebo, on treatment: no arm n for percent
- Tirzepatide Placebo: no arm n for percent
- Tirzepatide 5 mg: no arm n for percent
- Tirzepatide 10 mg: no arm n for percent
- Tirzepatide 15 mg: no arm n for percent
- Tirzepatide 15 mg: no arm n for percent
- Tirzepatide Placebo: no arm n for percent
- Tirzepatide 10 mg: no arm n for percent
- Tirzepatide Tirzepatide (lead-in): no arm n for percent
- Tirzepatide Tirzepatide MTD: no arm n for percent
- Tirzepatide Placebo: no arm n for percent
- Tirzepatide Tirzepatide: no arm n for percent
- Tirzepatide Placebo: no arm n for percent
- Tirzepatide Tirzepatide: no arm n for percent
- Tirzepatide Placebo: no arm n for percent
- Tirzepatide Tirzepatide MTD_GPI1: no arm n for percent
- Tirzepatide Placebo_GPI1: no arm n for percent
- Tirzepatide Tirzepatide MTD_GPI2: no arm n for percent
- Tirzepatide Placebo_GPI2: no arm n for percent
- Tirzepatide 15 mg: no arm n for percent
- Tirzepatide Placebo: no arm n for percent
- Tirzepatide 10 mg: no arm n for percent
- Tirzepatide 15 mg: no arm n for percent
- Tirzepatide Placebo: no arm n for percent
- Tirzepatide 10 mg: no arm n for percent
- Orforglipron Placebo: no arm n for percent
- Orforglipron 6 mg: no arm n for percent
- Orforglipron 12 mg: no arm n for percent
- Orforglipron Placebo QD: no arm n for percent
- Orforglipron 6 mg: no arm n for percent
- Orforglipron 12 mg: no arm n for percent
- Cagrilintide/semaglutide cagrilintide 2.4 mg and semaglutide 2.4 mg: no arm n for percent
- Cagrilintide/semaglutide Placebo s.c.: no arm n for percent
- Retatrutide 4 mg: no arm n for percent
- Retatrutide 9 mg: no arm n for percent
- Retatrutide 12 mg: no arm n for percent
- Retatrutide Placebo: no arm n for percent
- Survodutide 3.6 mg: no arm n for percent
- Survodutide 6.0 mg: no arm n for percent
- Survodutide Placebo: no arm n for percent
- Survodutide 0.6 mg: no arm n for percent
- Survodutide Placebo group: no arm n for percent
- Survodutide 2.4 mg: no arm n for percent
- Survodutide 3.6 mg: no arm n for percent
- Survodutide 4.8 mg: no arm n for percent
- VK2735 2.5 mg: no arm n for percent
- VK2735 15 mg: no arm n for percent
- VK2735 Placebo 13 weeks: no arm n for percent
- Eloralintide Placebo: no arm n for percent
- Eloralintide 1 mg: no arm n for percent
- Eloralintide 3 mg: no arm n for percent
- Eloralintide 6 mg: no arm n for percent
- Eloralintide 9 mg: no arm n for percent
- Berobenatide Placebo: no arm n for percent
- Dulaglutide Dulaglutide Arm: no arm n for percent
- Dulaglutide Placebo Arm: no arm n for percent
- Exenatide Group A: no arm n for percent
- Exenatide Group B: no arm n for percent
- Exenatide Exenatide: no arm n for percent
- Exenatide Placebo: no arm n for percent
- Exenatide Exenatide once weekly (EQW ): no arm n for percent
- Exenatide Dapagliflozin (DAPA): no arm n for percent
- Exenatide EQW plus DAPA: no arm n for percent
- Exenatide Dapagliflozin plus Glucophage (MET ER): no arm n for percent
- Exenatide Phentermine /Topiramate (PHEN/ TPM) ER: no arm n for percent
- Exenatide Exenatide once weekly extended-release: no arm n for percent
- Exenatide Matching placebo: no arm n for percent
- Exenatide Group A: no arm n for percent
- Exenatide Group B: no arm n for percent
- Liraglutide 3.0mg: no arm n for percent
- Liraglutide 3.0mg: no arm n for percent
- Liraglutide Liraglutide Placebo, no Pre-diabetes: no arm n for percent
- Liraglutide Liraglutide Placebo, Pre-diabetes: no arm n for percent
- Liraglutide 3.0 mg: no arm n for percent
- Liraglutide 3.0 mg: no arm n for percent
- Liraglutide 1.8 mg: no arm n for percent
- Liraglutide Placebo: no arm n for percent
- Liraglutide 3.0 mg: no arm n for percent
- Liraglutide Placebo: no arm n for percent
- Liraglutide 3.0 mg: no arm n for percent
- Liraglutide Placebo: no arm n for percent
- Liraglutide 3.0 mg: no arm n for percent
- Liraglutide Placebo: no arm n for percent
- Liraglutide Semaglutide: no arm n for percent
- Liraglutide Liraglutide: no arm n for percent
- Liraglutide Placebo (liraglutide): no arm n for percent
- Liraglutide Liraglutide: no arm n for percent
- Liraglutide Placebo: no arm n for percent
- Liraglutide 3.0 mg: no arm n for percent
- Liraglutide Placebo, in trial: no arm n for percent
- Liraglutide Liraglutide: no arm n for percent
- Liraglutide Placebo: no arm n for percent
- Liraglutide Metformin XR plus liraglutide: no arm n for percent
- Liraglutide Metformin XR plus placebo: no arm n for percent
- Liraglutide Liraglutide Pen Injector (Saxenda): no arm n for percent
- Liraglutide Placebo liraglutide pen injector: no arm n for percent
- Liraglutide Liraglutide: no arm n for percent
- Liraglutide Placebo: no arm n for percent
- Liraglutide 0.05 mg: no arm n for percent
- Liraglutide 0.1 mg: no arm n for percent
- Liraglutide 0.2 mg: no arm n for percent
- Liraglutide 0.3 mg: no arm n for percent
- Liraglutide 0.4 mg: no arm n for percent
- Liraglutide 3.0 mg: no arm n for percent
- Liraglutide Placebo + Metformin: no arm n for percent
- Liraglutide Liraglutide + Metformin: no arm n for percent
- Liraglutide 100 mcg: no arm n for percent
- Liraglutide 200 mcg: no arm n for percent
- Liraglutide 300 mcg: no arm n for percent
- Liraglutide 2.4 mg: no arm n for percent
- Liraglutide 4.5 mg: no arm n for percent
- Liraglutide 1.2 mg: no arm n for percent
- Liraglutide 0.6 mg: no arm n for percent
- Liraglutide 0.3 mg: no arm n for percent
- Liraglutide 3.0 mg: no arm n for percent
- Liraglutide 3.0 mg: no arm n for percent
- Liraglutide 3.0 mg: no arm n for percent
- Liraglutide 3.0 mg: no arm n for percent
- Liraglutide 3.0 mg: no arm n for percent
- Liraglutide 3.0 mg: no arm n for percent
- Liraglutide Orlistat: no arm n for percent
- Lixisenatide Lixisenatide: no arm n for percent
- Lixisenatide Sitagliptin: no arm n for percent
- Mazdutide 3/6 Milligrams (mg) Mazdutide: no arm n for percent
- Mazdutide 10 mg: no arm n for percent
- Mazdutide 16 mg: no arm n for percent
- Mazdutide Placebo: no arm n for percent
- Mazdutide 6 mg: no arm n for percent
- Oral Semaglutide Oral semaglutide: no arm n for percent
- Oral Semaglutide Oral semaglutide placebo: no arm n for percent
- Oral Semaglutide 25 mg: no arm n for percent
- Oral Semaglutide Oral semaglutide placebo: no arm n for percent
- Oral Semaglutide 50 mg: no arm n for percent
- Oral Semaglutide oral semaglutide placebo once daily: no arm n for percent
- TERN-601 250 mg: no arm n for percent
- TERN-601 500 mg: no arm n for percent
- TERN-601 750 mg: no arm n for percent
- TERN-601 Matching Placebo: no arm n for percent
- CT-868 CT-868 Placebo: no arm n for percent
- CT-868 1.8 mg: no arm n for percent
- CT-868 4.1 mg: no arm n for percent
- CT-868 6.6 mg: no arm n for percent
- HM15211 HM15211: no arm n for percent
- HM15211 Placebo: no arm n for percent
- Pramlintide Placebo-P + Placebo-M: no arm n for percent
- Pramlintide 360 mcg: no arm n for percent
- Pramlintide 5.0 mg: no arm n for percent
- Pramlintide 2.5 mg: no arm n for percent
- Pramlintide 5.0 mg: no arm n for percent
- Pramlintide 1.25 mg: no arm n for percent
- Pramlintide 2.5 mg: no arm n for percent
- Pramlintide 5.0 mg: no arm n for percent
- Pramlintide 1: no arm n for percent
- Pramlintide 2: no arm n for percent
- Pramlintide 3: no arm n for percent
- Pramlintide Placebo: no arm n for percent
- Pramlintide Pramlintide + Metreleptin: no arm n for percent
- Pramlintide Pramlintide Acetate and Placebo: no arm n for percent
- Pramlintide Lead-In Period: no arm n for percent
- Bimagrumab 30 mg: no arm n for percent
- Bimagrumab 30 mg: no arm n for percent
- Bimagrumab 30 mg: no arm n for percent
- Bimagrumab 1.0 mg: no arm n for percent
- Bimagrumab 2.4 mg: no arm n for percent
- Bimagrumab 1.0 mg: no arm n for percent
- Bimagrumab 2.4 mg: no arm n for percent
- Naltrexone And Bupropion NB16: no arm n for percent
- Naltrexone And Bupropion NB32: no arm n for percent
- Naltrexone And Bupropion Placebo: no arm n for percent
- Naltrexone And Bupropion NB32: no arm n for percent
- Naltrexone And Bupropion Placebo: no arm n for percent
- Naltrexone And Bupropion NB32: no arm n for percent
- Naltrexone And Bupropion Placebo: no arm n for percent
- Naltrexone And Bupropion NB32: no arm n for percent
- Naltrexone And Bupropion Placebo: no arm n for percent
- Naltrexone And Bupropion BWL + NB medication: no arm n for percent
- Naltrexone And Bupropion BWL + Placebo: no arm n for percent
- Naltrexone And Bupropion Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication: no arm n for percent
- Naltrexone And Bupropion BWL + Placebo: no arm n for percent
- Naltrexone And Bupropion NB medication: no arm n for percent
- Naltrexone And Bupropion Placebo: no arm n for percent
- Naltrexone And Bupropion Naltrexone+Bupropion Medication: no arm n for percent
- Naltrexone And Bupropion Placebo: no arm n for percent
- Naltrexone And Bupropion Naltrexone/Bupropion: no arm n for percent
- Naltrexone And Bupropion Placebo: no arm n for percent
- Orlistat Intensive Lifestyle Mod. Intervention: no arm n for percent
- Orlistat Standard Lifestyle Intervention: no arm n for percent
- Orlistat Placebo: no arm n for percent
- Orlistat Orlistat: no arm n for percent
- Phentermine And Topiramate VI-0521 Low: no arm n for percent
- Phentermine And Topiramate VI-0521 Top: no arm n for percent
- Phentermine And Topiramate Placebo: no arm n for percent
- Phentermine And Topiramate VI-0521 Top: no arm n for percent
- Phentermine And Topiramate VI-0521 Mid: no arm n for percent
- Phentermine And Topiramate TPM 46: no arm n for percent
- Phentermine And Topiramate TPM 92: no arm n for percent
- Phentermine And Topiramate PHEN 7.5: no arm n for percent
- Phentermine And Topiramate PHEN 15: no arm n for percent
- Phentermine And Topiramate Placebo: no arm n for percent
- Phentermine And Topiramate LSMT 12: no arm n for percent
- Phentermine And Topiramate LSMT 24: no arm n for percent
- Phentermine And Topiramate Phentermine & Topiramate: no arm n for percent
- Phentermine And Topiramate Placebo Drugs: no arm n for percent
- Phentermine And Topiramate Semaglutide: no arm n for percent
- Phentermine And Topiramate Other anti-obesity medication: no arm n for percent
- Setmelanotide Setmelanotide: no arm n for percent
- Setmelanotide Placebo: no arm n for percent
- Setmelanotide Setmelanotide: no arm n for percent
- Setmelanotide Setmelanotide (Double-Blind): no arm n for percent
- Setmelanotide Placebo (Double-Blind): no arm n for percent
- Setmelanotide Setmelanotide (Open-label): no arm n for percent
- Setmelanotide Pivotal Cohort: no arm n for percent
- Setmelanotide 2 mg: no arm n for percent
- Setmelanotide 2.5 mg: no arm n for percent
- Setmelanotide 3 mg: no arm n for percent
- Setmelanotide 20 mg: no arm n for percent
- Setmelanotide 25 mg: no arm n for percent
- Setmelanotide 3 mg: no arm n for percent
- Setmelanotide 30 mg: no arm n for percent
- Setmelanotide 20 mg: no arm n for percent
- Setmelanotide 25 mg: no arm n for percent
- Setmelanotide 30 mg: no arm n for percent
- Setmelanotide Setmelanotide: no arm n for percent
- Setmelanotide Setmelanotide: no arm n for percent
- Setmelanotide Setmelanotide: PPL Group: no arm n for percent
- Setmelanotide Setmelanotide: BBS Group: no arm n for percent
- Setmelanotide 16p11.2 Cohort: no arm n for percent
- Setmelanotide AS Cohort: no arm n for percent
- Setmelanotide BBS Cohort: no arm n for percent
- Setmelanotide MC4R Cohort: no arm n for percent
- Setmelanotide POMC/PCSK1/LEPR Heterozygous Cohort: no arm n for percent
- Setmelanotide POMC/PCSK1/LEPR Composite Heterozygous Cohort: no arm n for percent
- Setmelanotide POMC/PCSK1/LEPR Compound Heterozygous Cohort: no arm n for percent
- Setmelanotide SH2B1 Cohort: no arm n for percent
- Setmelanotide SMS Cohort: no arm n for percent
- Setmelanotide SRC1 Cohort: no arm n for percent
- Setmelanotide Stage 1: Setmelanotide (Open-Label): no arm n for percent
- Setmelanotide Stage 2: Setmelanotide (Double-Blind): no arm n for percent
- Setmelanotide Stage 2: Placebo (Double-Blind): no arm n for percent
- Setmelanotide Placebo: no arm n for percent
- Setmelanotide Setmelanotide: no arm n for percent
- Setmelanotide Placebo: no arm n for percent
- Setmelanotide 0.5 mg: no arm n for percent
- Setmelanotide 1.5 mg: no arm n for percent
- Setmelanotide 2.5 mg: no arm n for percent
- Setmelanotide Placebo: no arm n for percent
- Sibutramine Sibutramine: no arm n for percent
- Sibutramine Placebo: no arm n for percent
- Tesofensine placebo arm: no arm n for percent
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation |
|---|---|---|---|---|
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide placebo | n/r | n/r | n/r | n/r |
| Semaglutide 7.2 mg | n/r | n/r | n/r | 5.4% |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r |
| Semaglutide Placebo | n/r | n/r | n/r | 1% |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r |
| Semaglutide Placebo (semaglutide) | 337 participants | 87 participants | 353 participants | n/r |
| Semaglutide 1.0 mg | 128 participants | 54 participants | 88 participants | n/r |
| Semaglutide 2.4 mg | 135 participants | 86 participants | 86 participants | n/r |
| Semaglutide Semaglutide placebo I/II | 37 participants | 11 participants | 48 participants | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r |
| Semaglutide Placebo | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r |
| Semaglutide Placebo, in trial | 13 participants | 8 participants | 19 participants | n/r |
| Semaglutide 15 mg | 163 participants | 56 participants | 88 participants | n/r |
| Semaglutide 2.4 mg | 167 participants | 80 participants | 88 participants | n/r |
| Semaglutide 2.4 mg | 55 participants | 26 participants | 42 participants | n/r |
| Semaglutide Semaglutide placebo OW | 18 participants | 7 participants | 20 participants | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide placebo | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | 237 participants | 111 participants | 147 participants | n/r |
| Semaglutide Placebo, in trial | 45 participants | 22 participants | 45 participants | n/r |
| Semaglutide Insuline glargine U100 (reduced) + semaglutide | n/r | n/r | n/r | n/r |
| Semaglutide Insuline glargine U100 (titrated) | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r |
| Semaglutide Placebo (semaglutide) | 7 participants | 3 participants | 10 participants | n/r |
| Semaglutide 7.2 mg | 89 participants | 51 participants | 56 participants | n/r |
| Semaglutide 2.4 mg | 29 participants | 14 participants | 21 participants | n/r |
| Semaglutide Placebo | 12 participants | 3 participants | 9 participants | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | 59 participants | 21 participants | 21 participants | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | 35 participants | 17 participants | 32 participants | n/r |
| Semaglutide 1.7 mg | n/r | n/r | n/r | n/r |
| Semaglutide 1.7 mg | 18 participants | 10 participants | 22 participants | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r |
| Semaglutide Placebo (semaglutide) | 9 participants | 0 participants | 13 participants | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r |
| Semaglutide Placebo | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | 81 participants | 46 participants | 53 participants | n/r |
| Semaglutide Placebo, in trial | 33 participants | 7 participants | 36 participants | n/r |
| Semaglutide Placebo | 2 participants | 0 participants | 6 participants | n/r |
| Semaglutide 2.4 mg | 29 participants | 16 participants | 30 participants | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r |
| Semaglutide Placebo (semaglutide) | 3 participants | 1 participants | 7 participants | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r |
| Semaglutide Placebo | 12 participants | 7 participants | 13 participants | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r |
| Semaglutide Placebo | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide, on treatment | n/r | n/r | n/r | n/r |
| Semaglutide Placebo, on treatment | 7 participants | 2 participants | 3 participants | n/r |
| Tirzepatide Placebo | n/r | n/r | n/r | n/r |
| Tirzepatide 5 mg | n/r | n/r | n/r | n/r |
| Tirzepatide 10 mg | n/r | n/r | n/r | n/r |
| Tirzepatide 15 mg | n/r | n/r | n/r | n/r |
| Tirzepatide 15 mg | 68 participants | 40 participants | 66 participants | n/r |
| Tirzepatide Placebo | 20 participants | 10 participants | 28 participants | n/r |
| Tirzepatide 10 mg | 63 participants | 34 participants | 62 participants | n/r |
| Tirzepatide Tirzepatide (lead-in) | 278 participants | 128 participants | 165 participants | n/r |
| Tirzepatide Tirzepatide MTD | 27 participants | 18 participants | 36 participants | n/r |
| Tirzepatide Placebo | 9 participants | 4 participants | 16 participants | n/r |
| Tirzepatide Tirzepatide | 62 participants | 38 participants | 65 participants | n/r |
| Tirzepatide Placebo | 23 participants | 7 participants | 23 participants | n/r |
| Tirzepatide Tirzepatide | 114 participants | 52 participants | 89 participants | n/r |
| Tirzepatide Placebo | 41 participants | 4 participants | 27 participants | n/r |
| Tirzepatide Tirzepatide MTD_GPI1 | 29 participants | 20 participants | 30 participants | n/r |
| Tirzepatide Placebo_GPI1 | 12 participants | 5 participants | 15 participants | n/r |
| Tirzepatide Tirzepatide MTD_GPI2 | 26 participants | 11 participants | 26 participants | n/r |
| Tirzepatide Placebo_GPI2 | 6 participants | 1 participants | 10 participants | n/r |
| Tirzepatide 15 mg | 18 participants | 9 participants | 7 participants | n/r |
| Tirzepatide Placebo | 3 participants | 3 participants | 3 participants | n/r |
| Tirzepatide 10 mg | 10 participants | 5 participants | 9 participants | n/r |
| Tirzepatide 15 mg | 23 participants | 14 participants | 29 participants | n/r |
| Tirzepatide Placebo | 4 participants | 3 participants | 6 participants | n/r |
| Tirzepatide 10 mg | 21 participants | 8 participants | 28 participants | n/r |
| Orforglipron Placebo | 53 participants | 24 participants | 94 participants | n/r |
| Orforglipron 6 mg | 66 participants | 42 participants | 70 participants | n/r |
| Orforglipron 12 mg | 103 participants | 67 participants | 82 participants | n/r |
| Orforglipron Placebo QD | 0 participants | 0 participants | 2 participants | n/r |
| Orforglipron 6 mg | 8 participants | 4 participants | 9 participants | n/r |
| Orforglipron 12 mg | 9 participants | 5 participants | 4 participants | n/r |
| Cagrilintide/semaglutide cagrilintide 2.4 mg and semaglutide 2.4 mg | n/r | n/r | n/r | n/r |
| Cagrilintide/semaglutide Placebo s.c. | n/r | n/r | n/r | n/r |
| Retatrutide 4 mg | n/r | n/r | n/r | n/r |
| Retatrutide 9 mg | n/r | n/r | n/r | n/r |
| Retatrutide 12 mg | n/r | n/r | n/r | n/r |
| Retatrutide Placebo | n/r | n/r | n/r | n/r |
| Survodutide 3.6 mg | n/r | n/r | n/r | n/r |
| Survodutide 6.0 mg | n/r | n/r | n/r | n/r |
| Survodutide Placebo | n/r | n/r | n/r | n/r |
| Survodutide 0.6 mg | 36 participants | 13 participants | 22 participants | n/r |
| Survodutide Placebo group | 15 participants | 4 participants | 8 participants | n/r |
| Survodutide 2.4 mg | 60 participants | 28 participants | 21 participants | n/r |
| Survodutide 3.6 mg | 45 participants | 28 participants | 17 participants | n/r |
| Survodutide 4.8 mg | 32 participants | 13 participants | 9 participants | n/r |
| VK2735 2.5 mg | n/r | n/r | n/r | n/r |
| VK2735 15 mg | n/r | n/r | n/r | n/r |
| VK2735 Placebo 13 weeks | n/r | n/r | n/r | n/r |
| Eloralintide Placebo | n/r | n/r | n/r | n/r |
| Eloralintide 1 mg | n/r | n/r | n/r | n/r |
| Eloralintide 3 mg | n/r | n/r | n/r | n/r |
| Eloralintide 6 mg | n/r | n/r | n/r | n/r |
| Eloralintide 9 mg | n/r | n/r | n/r | n/r |
| Berobenatide Placebo | 13 participants | 6 participants | 5 participants | n/r |
| Dulaglutide Dulaglutide Arm | 2 participants | n/r | n/r | n/r |
| Dulaglutide Placebo Arm | 1 participants | n/r | n/r | n/r |
| Exenatide Group A | 43 participants | 21 participants | 18 participants | n/r |
| Exenatide Group B | 19 participants | 9 participants | 21 participants | n/r |
| Exenatide Exenatide | 24 participants | 11 participants | 16 participants | n/r |
| Exenatide Placebo | 19 participants | 8 participants | 16 participants | n/r |
| Exenatide Exenatide once weekly (EQW ) | n/r | n/r | n/r | n/r |
| Exenatide Dapagliflozin (DAPA) | n/r | n/r | n/r | n/r |
| Exenatide EQW plus DAPA | n/r | n/r | n/r | n/r |
| Exenatide Dapagliflozin plus Glucophage (MET ER) | n/r | n/r | n/r | n/r |
| Exenatide Phentermine /Topiramate (PHEN/ TPM) ER | n/r | n/r | n/r | n/r |
| Exenatide Exenatide once weekly extended-release | 6 participants | 4 participants | 7 participants | n/r |
| Exenatide Matching placebo | 3 participants | 4 participants | 3 participants | n/r |
| Exenatide Group A | 18 participants | 6 participants | 10 participants | n/r |
| Exenatide Group B | 3 participants | 1 participants | 2 participants | n/r |
| Liraglutide 3.0mg | n/r | n/r | n/r | n/r |
| Liraglutide 3.0mg | n/r | n/r | n/r | n/r |
| Liraglutide Liraglutide Placebo, no Pre-diabetes | 78 participants | 25 participants | 46 participants | n/r |
| Liraglutide Liraglutide Placebo, Pre-diabetes | 128 participants | 42 participants | 107 participants | n/r |
| Liraglutide 3.0 mg | 622 participants | 300 participants | 388 participants | n/r |
| Liraglutide 3.0 mg | 138 participants | 66 participants | 108 participants | n/r |
| Liraglutide 1.8 mg | 66 participants | 21 participants | 37 participants | n/r |
| Liraglutide Placebo | 29 participants | 12 participants | 27 participants | n/r |
| Liraglutide 3.0 mg | 101 participants | 35 participants | 38 participants | n/r |
| Liraglutide Placebo | 36 participants | 5 participants | 26 participants | n/r |
| Liraglutide 3.0 mg | 58 participants | 32 participants | 45 participants | n/r |
| Liraglutide Placebo | 23 participants | 12 participants | 30 participants | n/r |
| Liraglutide 3.0 mg | 47 participants | 13 participants | 29 participants | n/r |
| Liraglutide Placebo | 12 participants | 5 participants | 14 participants | n/r |
| Liraglutide Semaglutide | n/r | n/r | n/r | n/r |
| Liraglutide Liraglutide | n/r | n/r | n/r | n/r |
| Liraglutide Placebo (liraglutide) | 19 participants | 5 participants | 22 participants | n/r |
| Liraglutide Liraglutide | n/r | n/r | n/r | n/r |
| Liraglutide Placebo | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | 68 participants | 33 participants | 31 participants | n/r |
| Liraglutide Placebo, in trial | 25 participants | 7 participants | 23 participants | n/r |
| Liraglutide Liraglutide | 53 participants | 43 participants | 28 participants | n/r |
| Liraglutide Placebo | 18 participants | 5 participants | 18 participants | n/r |
| Liraglutide Metformin XR plus liraglutide | 29 participants | n/r | 14 participants | n/r |
| Liraglutide Metformin XR plus placebo | 2 participants | n/r | 13 participants | n/r |
| Liraglutide Liraglutide Pen Injector (Saxenda) | 14 participants | 5 participants | 4 participants | n/r |
| Liraglutide Placebo liraglutide pen injector | 3 participants | 0 participants | 0 participants | n/r |
| Liraglutide Liraglutide | 1 participants | 2 participants | 10 participants | n/r |
| Liraglutide Placebo | 0 participants | 0 participants | 2 participants | n/r |
| Liraglutide 0.05 mg | 32 participants | 8 participants | 20 participants | n/r |
| Liraglutide 0.1 mg | 42 participants | 18 participants | 25 participants | n/r |
| Liraglutide 0.2 mg | 45 participants | 24 participants | 35 participants | n/r |
| Liraglutide 0.3 mg | 43 participants | 11 participants | 27 participants | n/r |
| Liraglutide 0.4 mg | 49 participants | 17 participants | 38 participants | n/r |
| Liraglutide 3.0 mg | 46 participants | 11 participants | 29 participants | n/r |
| Liraglutide Placebo + Metformin | 12 participants | 5 participants | 10 participants | n/r |
| Liraglutide Liraglutide + Metformin | 17 participants | 3 participants | 4 participants | n/r |
| Liraglutide 100 mcg | 23 participants | 10 participants | 13 participants | n/r |
| Liraglutide 200 mcg | 85 participants | 51 participants | 49 participants | n/r |
| Liraglutide 300 mcg | 105 participants | 43 participants | 28 participants | n/r |
| Liraglutide 2.4 mg | 32 participants | 9 participants | 18 participants | n/r |
| Liraglutide 4.5 mg | 47 participants | 8 participants | 7 participants | n/r |
| Liraglutide 1.2 mg | 37 participants | 5 participants | 8 participants | n/r |
| Liraglutide 0.6 mg | 27 participants | 6 participants | 10 participants | n/r |
| Liraglutide 0.3 mg | 20 participants | 6 participants | 15 participants | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | 39 participants | 20 participants | 18 participants | n/r |
| Liraglutide 3.0 mg | 29 participants | 6 participants | 20 participants | n/r |
| Liraglutide 3.0 mg | 35 participants | 12 participants | 15 participants | n/r |
| Liraglutide 3.0 mg | 34 participants | 13 participants | 16 participants | n/r |
| Liraglutide 3.0 mg | 47 participants | 13 participants | 18 participants | n/r |
| Liraglutide Orlistat | 8 participants | 0 participants | 33 participants | n/r |
| Lixisenatide Lixisenatide | n/r | n/r | n/r | n/r |
| Lixisenatide Sitagliptin | n/r | n/r | n/r | n/r |
| Mazdutide 3/6 Milligrams (mg) Mazdutide | 14 participants | 7 participants | 9 participants | n/r |
| Mazdutide 10 mg | 22 participants | 6 participants | 12 participants | n/r |
| Mazdutide 16 mg | 34 participants | 24 participants | 13 participants | n/r |
| Mazdutide Placebo | 12 participants | 1 participants | 6 participants | n/r |
| Mazdutide 6 mg | n/r | n/r | n/r | n/r |
| Oral Semaglutide Oral semaglutide | 173 participants | 80 participants | 89 participants | n/r |
| Oral Semaglutide Oral semaglutide placebo | 51 participants | 12 participants | 56 participants | n/r |
| Oral Semaglutide 25 mg | 95 participants | 63 participants | 36 participants | n/r |
| Oral Semaglutide Oral semaglutide placebo | 19 participants | 6 participants | 9 participants | n/r |
| Oral Semaglutide 50 mg | 34 participants | 20 participants | 22 participants | n/r |
| Oral Semaglutide oral semaglutide placebo once daily | 5 participants | 2 participants | 6 participants | n/r |
| TERN-601 250 mg | 16 participants | 2 participants | 4 participants | n/r |
| TERN-601 500 mg | 17 participants | 10 participants | 4 participants | n/r |
| TERN-601 750 mg | 20 participants | 11 participants | 1 participants | n/r |
| TERN-601 Matching Placebo | 3 participants | 0 participants | 2 participants | n/r |
| CT-868 CT-868 Placebo | 2 participants | 0 participants | 2 participants | n/r |
| CT-868 1.8 mg | 13 participants | 4 participants | 6 participants | n/r |
| CT-868 4.1 mg | 17 participants | 8 participants | 6 participants | n/r |
| CT-868 6.6 mg | 9 participants | 8 participants | 6 participants | n/r |
| HM15211 HM15211 | 1 participants | 1 participants | n/r | n/r |
| HM15211 Placebo | 1 participants | 1 participants | n/r | n/r |
| Pramlintide Placebo-P + Placebo-M | 4 participants | 0 participants | 5 participants | n/r |
| Pramlintide 360 mcg | 31 participants | 6 participants | 5 participants | n/r |
| Pramlintide 5.0 mg | 4 participants | 3 participants | 3 participants | n/r |
| Pramlintide 2.5 mg | 27 participants | 0 participants | 5 participants | n/r |
| Pramlintide 5.0 mg | 21 participants | 2 participants | 4 participants | n/r |
| Pramlintide 1.25 mg | 26 participants | 5 participants | 4 participants | n/r |
| Pramlintide 2.5 mg | 29 participants | 1 participants | 7 participants | n/r |
| Pramlintide 5.0 mg | 19 participants | 1 participants | 3 participants | n/r |
| Pramlintide 1 | 3 participants | 0 participants | 1 participants | n/r |
| Pramlintide 2 | 2 participants | 0 participants | 2 participants | n/r |
| Pramlintide 3 | 5 participants | 0 participants | 1 participants | n/r |
| Pramlintide Placebo | 1 participants | n/r | n/r | n/r |
| Pramlintide Pramlintide + Metreleptin | 7 participants | n/r | n/r | n/r |
| Pramlintide Pramlintide Acetate and Placebo | 7 participants | 2 participants | 0 participants | n/r |
| Pramlintide Lead-In Period | 10 participants | 3 participants | 2 participants | n/r |
| Bimagrumab 30 mg | 9 participants | 1 participants | 10 participants | n/r |
| Bimagrumab 30 mg | 15 participants | 5 participants | 27 participants | n/r |
| Bimagrumab 30 mg | 20 participants | 7 participants | 25 participants | n/r |
| Bimagrumab 1.0 mg | 25 participants | 6 participants | 19 participants | n/r |
| Bimagrumab 2.4 mg | 26 participants | 10 participants | 21 participants | n/r |
| Bimagrumab 1.0 mg | 23 participants | 6 participants | 27 participants | n/r |
| Bimagrumab 2.4 mg | 34 participants | 10 participants | 29 participants | n/r |
| Naltrexone And Bupropion NB16 | 155 participants | 36 participants | 31 participants | n/r |
| Naltrexone And Bupropion NB32 | 171 participants | 56 participants | 26 participants | n/r |
| Naltrexone And Bupropion Placebo | 30 participants | 14 participants | 28 participants | n/r |
| Naltrexone And Bupropion NB32 | 290 participants | 84 participants | 55 participants | n/r |
| Naltrexone And Bupropion Placebo | 34 participants | 10 participants | 18 participants | n/r |
| Naltrexone And Bupropion NB32 | 199 participants | 64 participants | 43 participants | n/r |
| Naltrexone And Bupropion Placebo | 21 participants | 13 participants | 15 participants | n/r |
| Naltrexone And Bupropion NB32 | 141 participants | 61 participants | 52 participants | n/r |
| Naltrexone And Bupropion Placebo | 12 participants | 6 participants | 16 participants | n/r |
| Naltrexone And Bupropion BWL + NB medication | 13 participants | 1 participants | 3 participants | n/r |
| Naltrexone And Bupropion BWL + Placebo | 5 participants | 0 participants | 9 participants | n/r |
| Naltrexone And Bupropion Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication | 7 participants | 2 participants | 3 participants | n/r |
| Naltrexone And Bupropion BWL + Placebo | 0 participants | 0 participants | 3 participants | n/r |
| Naltrexone And Bupropion NB medication | 8 participants | 3 participants | 2 participants | n/r |
| Naltrexone And Bupropion Placebo | 3 participants | 3 participants | 5 participants | n/r |
| Naltrexone And Bupropion Naltrexone+Bupropion Medication | 0 participants | n/r | n/r | n/r |
| Naltrexone And Bupropion Placebo | 1 participants | n/r | n/r | n/r |
| Naltrexone And Bupropion Naltrexone/Bupropion | 0 participants | 0 participants | 0 participants | n/r |
| Naltrexone And Bupropion Placebo | 0 participants | 0 participants | 0 participants | n/r |
| Orlistat Intensive Lifestyle Mod. Intervention | n/r | n/r | 35 participants | n/r |
| Orlistat Standard Lifestyle Intervention | n/r | n/r | 9 participants | n/r |
| Orlistat Placebo | 9 participants | 7 participants | 8 participants | n/r |
| Orlistat Orlistat | 10 participants | 7 participants | 21 participants | n/r |
| Phentermine And Topiramate VI-0521 Low | 14 participants | n/r | 12 participants | n/r |
| Phentermine And Topiramate VI-0521 Top | 37 participants | n/r | 24 participants | n/r |
| Phentermine And Topiramate Placebo | 24 participants | n/r | 23 participants | n/r |
| Phentermine And Topiramate VI-0521 Top | 8 participants | n/r | 6 participants | n/r |
| Phentermine And Topiramate VI-0521 Mid | 9 participants | n/r | 4 participants | n/r |
| Phentermine And Topiramate TPM 46 | 8 participants | n/r | 3 participants | n/r |
| Phentermine And Topiramate TPM 92 | 5 participants | n/r | 6 participants | n/r |
| Phentermine And Topiramate PHEN 7.5 | 5 participants | n/r | 1 participants | n/r |
| Phentermine And Topiramate PHEN 15 | 6 participants | n/r | 4 participants | n/r |
| Phentermine And Topiramate Placebo | 5 participants | n/r | 5 participants | n/r |
| Phentermine And Topiramate LSMT 12 | 0 participants | n/r | n/r | n/r |
| Phentermine And Topiramate LSMT 24 | 1 participants | n/r | n/r | n/r |
| Phentermine And Topiramate Phentermine & Topiramate | n/r | n/r | 1 participants | n/r |
| Phentermine And Topiramate Placebo Drugs | n/r | n/r | 3 participants | n/r |
| Phentermine And Topiramate Semaglutide | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate Other anti-obesity medication | n/r | n/r | n/r | n/r |
| Setmelanotide Setmelanotide | 28 participants | 21 participants | 17 participants | n/r |
| Setmelanotide Placebo | 17 participants | 14 participants | 14 participants | n/r |
| Setmelanotide Setmelanotide | 49 participants | 36 participants | 19 participants | n/r |
| Setmelanotide Setmelanotide (Double-Blind) | 7 participants | 7 participants | 2 participants | n/r |
| Setmelanotide Placebo (Double-Blind) | 6 participants | 0 participants | 1 participants | n/r |
| Setmelanotide Setmelanotide (Open-label) | 8 participants | 8 participants | 7 participants | n/r |
| Setmelanotide Pivotal Cohort | n/r | n/r | n/r | n/r |
| Setmelanotide 2 mg | 0 participants | 0 participants | 0 participants | n/r |
| Setmelanotide 2.5 mg | 0 participants | 0 participants | 0 participants | n/r |
| Setmelanotide 3 mg | 0 participants | 0 participants | 0 participants | n/r |
| Setmelanotide 20 mg | 0 participants | 0 participants | 0 participants | n/r |
| Setmelanotide 25 mg | 1 participants | 0 participants | 0 participants | n/r |
| Setmelanotide 3 mg | 3 participants | 2 participants | 2 participants | n/r |
| Setmelanotide 30 mg | 0 participants | 0 participants | 0 participants | n/r |
| Setmelanotide 20 mg | 0 participants | 0 participants | 0 participants | n/r |
| Setmelanotide 25 mg | 1 participants | 0 participants | 0 participants | n/r |
| Setmelanotide 30 mg | 0 participants | 1 participants | 2 participants | n/r |
| Setmelanotide Setmelanotide | 8 participants | 2 participants | 7 participants | n/r |
| Setmelanotide Setmelanotide | 8 participants | 8 participants | 5 participants | n/r |
| Setmelanotide Setmelanotide: PPL Group | n/r | 4 participants | 2 participants | n/r |
| Setmelanotide Setmelanotide: BBS Group | n/r | 3 participants | 0 participants | n/r |
| Setmelanotide 16p11.2 Cohort | 9 participants | 1 participants | 1 participants | n/r |
| Setmelanotide AS Cohort | 1 participants | 0 participants | 0 participants | n/r |
| Setmelanotide BBS Cohort | 3 participants | 2 participants | 2 participants | n/r |
| Setmelanotide MC4R Cohort | 12 participants | 7 participants | 7 participants | n/r |
| Setmelanotide POMC/PCSK1/LEPR Heterozygous Cohort | 14 participants | 4 participants | 3 participants | n/r |
| Setmelanotide POMC/PCSK1/LEPR Composite Heterozygous Cohort | 4 participants | 2 participants | 0 participants | n/r |
| Setmelanotide POMC/PCSK1/LEPR Compound Heterozygous Cohort | 13 participants | 6 participants | 1 participants | n/r |
| Setmelanotide SH2B1 Cohort | 13 participants | 6 participants | 4 participants | n/r |
| Setmelanotide SMS Cohort | 2 participants | 0 participants | 4 participants | n/r |
| Setmelanotide SRC1 Cohort | 11 participants | 4 participants | 1 participants | n/r |
| Setmelanotide Stage 1: Setmelanotide (Open-Label) | 75 participants | 41 participants | 22 participants | n/r |
| Setmelanotide Stage 2: Setmelanotide (Double-Blind) | 4 participants | 3 participants | 2 participants | n/r |
| Setmelanotide Stage 2: Placebo (Double-Blind) | 0 participants | 0 participants | 0 participants | n/r |
| Setmelanotide Placebo | 0 participants | 0 participants | 0 participants | n/r |
| Setmelanotide Setmelanotide | 5 participants | 0 participants | 1 participants | n/r |
| Setmelanotide Placebo | 3 participants | 2 participants | 0 participants | n/r |
| Setmelanotide 0.5 mg | 0 participants | n/r | n/r | n/r |
| Setmelanotide 1.5 mg | 0 participants | n/r | n/r | n/r |
| Setmelanotide 2.5 mg | 0 participants | n/r | n/r | n/r |
| Setmelanotide Placebo | 1 participants | n/r | n/r | n/r |
| Sibutramine Sibutramine | 0 participants | 0 participants | 0 participants | n/r |
| Sibutramine Placebo | 5 participants | 5 participants | 7 participants | n/r |
| Tesofensine placebo arm | 2 participants | 2 participants | 2 participants | n/r |
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.